Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9795125 | 0.84 | PIK3CD (0.35) | MAPT | |
| SCHEMBL23341080 | 0.83 | MAPT (0.31) | MAPT | |
| SCHEMBL24383380 | 0.81 | MAPT (0.30) | MAPT | |
| SCHEMBL25129056 | 0.81 | CHRM1 (0.32) | CACNA1H | |
| SCHEMBL22661082 | 0.79 | BCHE (0.31) | CACNA1HBCHE | |
| SCHEMBL26750247 | 0.78 | DNM1 (0.42) | CACNA1HPDE4B | |
| SCHEMBL12384306 | 0.78 | SIGMAR1 (0.46) | MAPT | |
| SCHEMBL5965047 | 0.75 | EGFR (0.37) | — | |
| SCHEMBL13781506 | 0.75 | MEN1 (0.39) | ALDH1A1 | |
| SCHEMBL14932882 | 0.73 | CACNA1H (0.36) | CACNA1HBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2022-05-05 | — | — | US | disclosed |
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| WO-2021127460-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20200247796-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9315451-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20080132500-A1 | Antibiotic compounds | MERCK SHARP & DOHME CORP. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, PGM2 | CACNA1H 3590/4885MAPT 1660/4885BCHE 837/4885 |
| US-20200247796-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | CACNA1H 3234/4885MAPT 1193/4885BCHE 3724/4885 |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | CACNA1H 622/4885MAPT 103/4885BCHE 3672/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | CACNA1H 622/4885MAPT 103/4885BCHE 3672/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | CACNA1H 622/4885MAPT 103/4885BCHE 3672/4885 |
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | ZC3HAV1, ZC3HAV1L, RPL35 | CACNA1H 3820/4885MAPT 2766/4885BCHE 4126/4885 |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | CACNA1H 3268/4885MAPT 1171/4885BCHE 3707/4885 |
| US-20080132500-A1 | Antibiotic compounds | NRDC, MRPL21, PEPD | CACNA1H 4827/4885MAPT 2550/4885BCHE 3373/4885 |
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | PLK1, CDK1, AURKC | CACNA1H 3234/4885MAPT 1193/4885BCHE 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.